Alto Neuroscience (ANRO) News Today → Massive breakthrough for options traders. (From WealthPress) (Ad) Free ANRO Stock Alerts $14.18 +0.05 (+0.35%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAlto Neuroscience (NYSE:ANRO) Shares Up 1.8%americanbankingnews.com - April 24 at 3:02 AMTreatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscapemarkets.businessinsider.com - April 23 at 6:25 PMAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophreniabusinesswire.com - April 23 at 8:05 AMAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorderfinance.yahoo.com - April 3 at 10:47 AMAlto Neuroscience, Inc. (NYSE:ANRO) CFO Purchases $100,614.00 in Stockinsidertrades.com - April 2 at 4:26 AMAlto Neuroscience, Inc. (NYSE:ANRO) CFO Nicholas Conrad Smith Buys 6,150 Sharesmarketbeat.com - April 1 at 6:32 PMBuy Rating Affirmed for Alto Neuroscience on Strong Pipeline and Solid Financialsmarkets.businessinsider.com - March 25 at 5:37 PMStifel Nicolaus Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)markets.businessinsider.com - March 25 at 5:37 PMStifel Nicolaus Reaffirms "Buy" Rating for Alto Neuroscience (NYSE:ANRO)marketbeat.com - March 25 at 12:16 PMBuy Rating Affirmed: Alto Neuroscience’s Promising Clinical Trials Signal Market Potentialmarkets.businessinsider.com - March 25 at 5:26 AMAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlightsbusinesswire.com - March 21 at 4:05 PMAlto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directorsfinance.yahoo.com - March 11 at 8:16 AMAlto Neuroscience to Participate in Upcoming Investor Conferencesfinance.yahoo.com - March 7 at 12:30 PMWilliam Blair Comments on Alto Neuroscience, Inc.'s FY2023 Earnings (NYSE:ANRO)marketbeat.com - February 29 at 7:39 AMAnalysts bullish on Alto Neuroscienceuk.investing.com - February 27 at 2:16 PMStifel, Baird, Jefferies bullish on Alto Neuroscience, cite upcoming datamsn.com - February 27 at 2:16 PMBuy Rating Affirmed for Alto Neuroscience Amid Promising Precision Neuropsychiatric Treatmentsmarkets.businessinsider.com - February 27 at 9:16 AMAlto Neuroscience (NYSE:ANRO) Now Covered by William Blairmarketbeat.com - February 27 at 8:21 AMAlto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conferencebusinesswire.com - February 27 at 8:00 AMAlto Neuroscience Inc ANROmorningstar.com - February 13 at 9:34 PMAlto Neuroscience Inc (ANRO)uk.investing.com - February 13 at 11:33 AMAlto Neuroscience, Inc.cnn.com - February 13 at 11:33 AMAlto Neuroscience, Inc. (ANRO)finance.yahoo.com - February 12 at 8:18 AMAlto Neuroscience Announces Pricing of Upsized Initial Public Offeringfinance.yahoo.com - February 12 at 8:18 AMAlto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Sharesfinance.yahoo.com - February 12 at 8:18 AM Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy ANRO Media Mentions By Week ANRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANRO News Sentiment▼0.200.33▲Average Medical News Sentiment ANRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANRO Articles This Week▼32▲ANRO Articles Average Week Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Neurogene News Today PepGen News Today Biomea Fusion News Today Harrow Health News Today Lexicon Pharmaceuticals News Today Heron Therapeutics News Today ADC Therapeutics News Today Nature's Sunshine Products News Today Corbus Pharmaceuticals News Today Esperion Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANRO) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
